Stocktoria
CAPRICOR THERAPEUTICS, INC. CAPR
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2002-06-04
CAPRICOR THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244,898 |
| R&D expense | $84.5M | $50.0M | $36.4M | $21.8M | $13.6M |
| Operating income | -$108.1M | -$42.6M | -$24.1M | -$29.7M | -$20.9M |
| Income tax | $1,600 | $1,600 | — | — | — |
| Net income | -$105.0M | -$40.5M | -$22.3M | -$29.0M | -$20.0M |
| EPS (diluted) | $-2.26 | $-1.15 | $-0.83 | $-1.18 | $-0.87 |
| Operating cash flow | -$69.8M | -$40.0M | -$25.6M | $4.9M | -$16.8M |
| Free cash flow | -$72.7M | -$41.2M | -$26.9M | $2.9M | -$18.0M |
| Cash & equivalents | $287.8M | $11.3M | $14.7M | $9.6M | $34.9M |
| Total assets | $355.9M | $170.5M | $58.7M | $50.1M | $41.3M |
| Total liabilities | $50.2M | $25.0M | $36.1M | $38.3M | $10.0M |
| Shareholders' equity | $305.8M | $145.5M | $22.6M | $11.8M | $31.4M |
Source: SEC EDGAR filings · CIK 0001133869 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.